Argenx (ARGX) announced that Health Canada has issued a notice of compliance authorizing Vyvgart as a monotherapy for the treatment of adult patients with active chronic inflammatory demyelinating polyneuropathy. Vyvgart is authorized for CIDP as a once weekly 20-30 second subcutaneous injection in a prefilled syringe.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARGX:
- Argenx price target raised to $930 from $820 at Piper Sandler
- Argenx price target raised to EUR 675 from EUR 655 at Deutsche Bank
- Argenx price target raised to $950 from $918 at Truist
- Argenx’s Earnings Call: Record Growth and Strategic Success
- Argenx price target raised to $910 from $775 at Evercore ISI